Oncotelic Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company focused on oncology, immunotherapy and rare-disease therapeutics. Company updates cover its internal drug pipeline, orphan oncology programs, antisense and small molecule injectable drug candidates, and partnerships or joint ventures used to license and co-develop selected candidates.
Recurring OTLC news also includes the PDAOAI AI platform for research, biomarker discovery, regulatory processes and GMP-compliant robotics, the company's 45% interest in GMP Bio and related Sapu Bio and Sapu Nano programs, and completed portfolio actions such as field-specific monetization of N2B nose-to-brain delivery assets.
Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a BioMedWire editorial highlighting advances in CNS drug delivery. The company is developing a proprietary intranasal nose-to-brain (N2B) system aimed at bypassing the blood-brain barrier to enable rapid, targeted therapeutic delivery to the brain.
Oncotelic Therapeutics (OTCQB: OTLC) closed a strategic asset transfer with Lunai Bioworks (LNAI) on May 6, 2026, granting Lunai worldwide rights to Oncotelic’s N2B intranasal delivery system IP for biodefense and Alzheimer’s disease fields.
In return, Oncotelic received $12.5 million in Lunai Series B Convertible Preferred Stock and will retain N2B rights outside those fields (e.g., Parkinson’s, sexual dysfunction). The deal aims to accelerate CNS biodefense and AD development and position Oncotelic for government funding opportunities.
Oncotelic Therapeutics (OTLC) reported integration of approximately 28 million scientific abstracts into its PDAOAI platform and progress on a jointly developed AI-enabled robotics platform with TechForce Robotics.
The company said this integration embeds scientific knowledge into automated workflows for regulated pharmaceutical development and manufacturing. Initial deployments are expected in the coming weeks, and the company is preparing to scale production to support anticipated demand as it advances toward commercial launch.
Oncotelic Therapeutics (OTLC) provided a corporate update on April 24, 2026, affirming a partnership-driven strategy to advance its oncology and rare-disease pipeline. The company reported a $249.0 million balance-sheet increase tied to its joint venture with GMP Biotechnology via an independent third-party valuation and is pursuing additional collaborations to provide financial and commercialization support.
Management says the approach supports parallel development of multiple drug candidates while preserving a capital-efficient operating model and unlocking the company’s intellectual property value.
Oncotelic Therapeutics (OTCQB: OTLC) was featured in a BioMedWire editorial on April 23, 2026, highlighting how scientific progress is influencing biotech valuations.
The company is cited for using fair-value accounting under U.S. GAAP to reflect clinical advancement and for holding a 45% interest in GMP Bio, which was recently assessed at more than $1 billion in enterprise value.
Oncotelic Therapeutics (OTCQB: OTLC) was featured in a BioMedWire editorial on April 21, 2026 about how advancing drug pipelines are shaping biotech valuation under U.S. GAAP fair-value accounting.
The company holds a 45% stake in GMP Bio, recently measured at an enterprise value of more than $1 billion, and is presented as an example of science becoming a measurable financial asset.
Oncotelic Therapeutics (OTLC) reported FY2025 net income of $249.0M driven mainly by a $365.4M non-cash increase in the fair value of its GMP Bio joint-venture investment and a $111.6M deferred tax provision. The company reported $0.59 basic EPS, no product revenue, formalized JV subsidiaries Sapu Bio and Sapu Nano, advanced six Deciparticle™ candidates and completed a Phase 1 OT-101/IL-2 combination trial. The JV’s GMP manufacturing facility remained fully operational and the PDAOAI knowledge platform expanded substantially during 2025.
Oncotelic Therapeutics (OTCQB: OTLC) announced placement in an editorial published April 10, 2026 by AINewsWire, part of the Dynamic Brand Portfolio at InvestorBrandNetwork.
The piece links AI-driven manufacturing and continuous compliance to scalable efficiency and cost advantages, noting alignment with Oncotelic's biotech and advanced digital systems focus.
Oncotelic Therapeutics (OTLC) announced a strategic partnership with TechForce Robotics to commercialize a PDAOAI-enhanced, GMP-compliant robotics platform on April 2, 2026.
The integrated system targets automated material handling, real-time monitoring, audit-ready documentation (IQ/OQ/PQ) and scalable manufacturing through a joint development, manufacturing, and licensing agreement.
Sapu Nano (parent Oncotelic Therapeutics, OTCQB:OTLC) will introduce its Deciparticle™ nanomedicine platform and present its clinical pipeline at BIO-Europe Spring 2026 on March 25, 2026.
The company will highlight platform-level advantages—sub-20 nm design, improved pharmacokinetics, better tissue targeting, and reduced excipient toxicities—and two lead intravenous candidates: Sapu003 (everolimus for injection) and Sapu006 (docetaxel for injection), both entering Phase 1 trials. Sapu Nano is seeking strategic partnerships and co-development opportunities to advance clinical development and commercialization.